Dayvigo vs Trazodone: How to Switch Between Them Safely

Why Clinicians Consider a Switch

Trazodone is one of the most prescribed sleep aids in the United States despite having no FDA indication for insomnia. A 2014 analysis in the Journal of Clinical Sleep Medicine estimated that trazodone accounted for roughly 20% of all insomnia prescriptions written in primary care [1]. Clinicians often start patients on trazodone because it is inexpensive, non-scheduled, and familiar. But its side-effect profile, including orthostatic hypotension, daytime sedation, and the rare but serious risk of priapism, pushes some patients toward newer alternatives [2].

Dayvigo (lemborexant) received FDA approval in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance [3]. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly reduced subjective wake after sleep onset (sWASO) compared to placebo at 30 nights, with the 10 mg dose showing a least-squares mean difference of −20.4 minutes (P<0.001) [4]. No published randomized head-to-head trial compares these two drugs directly, so the decision to switch rests on indirect evidence, pharmacologic logic, and clinical judgment.

How the Two Drugs Differ Pharmacologically

These medications occupy different receptor neighborhoods entirely. Lemborexant blocks orexin-1 and orexin-2 receptors, suppressing the wake-promoting neuropeptide system without broadly depressing the central nervous system [3]. Trazodone's sedative effect comes primarily from histamine H1 receptor antagonism and 5-HT2A serotonin receptor blockade at the low doses (25 to 100 mg) used for sleep [2].

This receptor separation matters for switching. Drugs that share receptor targets require careful cross-tapering to avoid rebound or withdrawal effects. Because lemborexant and trazodone bind different targets, a patient discontinuing one can start the other without pharmacodynamic overlap creating additive sedation. The main concern is pharmacokinetic: lemborexant's half-life of 17 to 19 hours means residual drug persists into the next evening [3]. A clinician switching a patient from Dayvigo to trazodone should account for that first-night overlap, particularly in older adults or patients with hepatic impairment where clearance is slower.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommended orexin receptor antagonists (at that time, suvorexant) as a treatment option for sleep maintenance insomnia, while noting that "trazodone has insufficient evidence to determine its risk-benefit profile for chronic insomnia" [5]. That conditional assessment has not changed in subsequent AASM updates, giving Dayvigo a clearer evidence base than trazodone for long-term use.

Switching from Trazodone to Dayvigo

This is the more common clinical scenario. A patient on trazodone 50 to 100 mg nightly who experiences residual morning grogginess, weight gain, or inadequate sleep maintenance may be a candidate for a Dayvigo trial.

The protocol is straightforward. Stop trazodone on night one. Start lemborexant 5 mg on night two, taken within 5 to 10 minutes of bedtime with at least 7 hours of planned sleep ahead [3]. The one-night gap is not strictly required, but it allows trazodone (half-life 5 to 9 hours) to clear by roughly four to five half-lives before the new drug reaches steady state. Some clinicians skip the gap entirely and begin lemborexant the same night trazodone is stopped, especially when the patient's trazodone dose is 50 mg or less.

The 5 mg starting dose of lemborexant is appropriate for most adults. In SUNRISE-1, the 5 mg dose reduced latency to persistent sleep (LPS) by a mean of 7.1 minutes compared to placebo on polysomnography at 30 nights, with statistically significant improvements in sWASO as well [4]. Dose escalation to 10 mg can be considered after 7 to 14 nights if sleep maintenance remains problematic. Dr. David Neubauer, associate professor at Johns Hopkins Sleep Disorders Center, has noted that "the orexin antagonist class offers a different risk profile from older sedatives, with less respiratory depression and cognitive impairment the following day" [6].

Patients who have been on trazodone at higher doses (150 mg or above, which enters antidepressant territory) should not discontinue abruptly. A 7- to 14-day taper is appropriate for doses at or above 150 mg due to serotonergic discontinuation risk, with lemborexant initiation beginning after the taper concludes or during the final taper step.

Switching from Dayvigo to Trazodone

This direction is less common but occurs for two main reasons: cost and formulary access. Dayvigo's average wholesale price exceeds $400 per month without insurance, while generic trazodone costs $4 to $15 for a 30-day supply [7]. A patient losing insurance coverage or facing a formulary exclusion may need to switch.

Lemborexant can be stopped without tapering. The SUNRISE-2 trial (a 12-month study, N=949) included a 2-week randomized withdrawal phase and found no statistically significant rebound insomnia after abrupt discontinuation of lemborexant 5 mg or 10 mg compared to placebo [8]. Trazodone can be started the same night at 25 to 50 mg and titrated upward by 25 mg every 3 to 5 nights as needed.

Clinicians should warn patients about several differences they may notice. Trazodone produces more pronounced sedation at onset but may not sustain sleep as effectively through the second half of the night. Dry mouth and orthostatic lightheadedness are more common with trazodone. The Mendelson 2005 review in the Journal of Clinical Psychiatry noted that while trazodone reduced sleep latency in short-term studies, "controlled data supporting its use beyond a few weeks are lacking" [9]. That evidence gap is worth discussing with patients who were previously on Dayvigo for months.

What About Using Both Together?

Combination use is not standard practice, and no published trial has evaluated concurrent lemborexant plus trazodone. The Dayvigo prescribing information advises caution with CNS depressants [3]. Because both drugs cause somnolence through different pathways, additive sedation is a theoretical concern, particularly regarding next-day driving performance.

A limited scenario where temporary overlap occurs: a clinician cross-tapering a patient off high-dose trazodone while initiating Dayvigo might allow 2 to 3 nights of overlap at a reduced trazodone dose (25 mg) plus lemborexant 5 mg. This approach has been described in clinical practice but has no published safety data to support it. Monitor the patient for excessive daytime sleepiness during any overlap period.

Efficacy Comparison: What the Data Actually Show

No direct comparison trial exists. The evidence must be assembled from separate studies with different populations, endpoints, and study designs. Here is what the separate data sets report.

For Dayvigo, SUNRISE-1 showed that lemborexant 10 mg reduced sWASO by 28.7 minutes from baseline versus 8.3 minutes for placebo at 30 nights (P<0.001) [4]. Subjective sleep onset latency (sSOL) also improved, with the 10 mg group reporting 11.6 fewer minutes to fall asleep compared to placebo. The trial enrolled adults aged 55 and older, a population where insomnia and polypharmacy are both common.

For trazodone, evidence is sparser and older. A 2005 meta-review by Walsh and colleagues found that trazodone 50 to 100 mg improved sleep latency in short-term studies (1 to 2 weeks), but the effect diminished by week 2 in one of the few controlled trials available [9][10]. The AASM has consistently rated the evidence for trazodone in insomnia as low quality. Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at UCSF, stated in a 2020 Sleep Medicine Reviews commentary that "trazodone remains one of the most commonly prescribed sleep medications with one of the thinnest evidence bases supporting its use" [11].

These are not interchangeable data sets. SUNRISE-1 used polysomnography and ran for 30 nights with a large sample. The trazodone evidence comes from smaller, shorter studies with heterogeneous designs. Drawing definitive efficacy conclusions from indirect comparison would be misleading.

Safety and Side-Effect Profile Differences

The side-effect profiles diverge in clinically meaningful ways.

Dayvigo's most reported adverse events in SUNRISE-1 were somnolence (10% at 10 mg vs. 1% placebo) and headache [4]. Sleep paralysis and hypnagogic hallucinations occurred in under 1% of patients but are class effects of orexin antagonists. Lemborexant is a Schedule IV controlled substance, though abuse liability studies showed low euphoria scores compared to zolpidem [3].

Trazodone carries a broader adverse-effect profile. Orthostatic hypotension is the most clinically significant risk, particularly in elderly patients taking antihypertensives. Priapism is rare (estimated at 1 in 6,000 to 1 in 8,000 male patients) but constitutes a urologic emergency [2]. Cardiac QT prolongation has been reported at higher doses. Trazodone is not a controlled substance, which simplifies prescribing logistics.

For patients with comorbid depression, trazodone's serotonergic activity may offer a marginal benefit, though the 25 to 100 mg sleep doses are well below the 150 to 400 mg antidepressant range. Dayvigo has no antidepressant properties but also does not worsen depression per SUNRISE trial safety data [4][8].

Special Populations: Who Should Be Extra Careful

Older adults represent the largest group switching between these drugs. The American Geriatrics Society Beers Criteria does not list orexin antagonists among potentially inappropriate medications for older adults but does flag antihistamines and anticholinergic drugs [12]. Trazodone's antihistaminic and alpha-adrenergic blocking properties make falls a concern in this group. Lemborexant 5 mg was specifically studied in adults aged 55 and older in SUNRISE-1, providing age-specific safety data that trazodone lacks [4].

Patients with hepatic impairment need dose adjustments for both drugs. The lemborexant recommended starting dose drops to 5 mg (maximum 5 mg) in moderate hepatic impairment, and the drug is not recommended in severe impairment [3]. Trazodone clearance is also reduced in liver disease, but no formal dose adjustment guidance exists in its label. When switching in this population, a longer washout (2 to 3 nights between drugs) is reasonable.

Patients on CYP3A4 inhibitors (ketoconazole, clarithromycin, certain HIV protease inhibitors) should avoid lemborexant or use the 5 mg maximum dose, as these drugs can more than double lemborexant exposure [3]. Trazodone is metabolized by CYP3A4 as well but is less sensitive to inhibition at sleep-range doses.

A Practical Switching Timeline

For the most common scenario (trazodone to Dayvigo), a reasonable protocol:

Night 1: Last dose of trazodone at the usual time. Night 2: No sleep medication (optional washout night; can be skipped if trazodone dose was 50 mg or less). Night 3: Begin lemborexant 5 mg, taken immediately before bed. Nights 3 through 16: Assess response. If sleep maintenance remains poor after 14 nights, consider increasing to 10 mg. Day 7 and Day 30: Follow-up to evaluate subjective sleep quality, daytime function, and any new side effects.

For the reverse switch (Dayvigo to trazodone):

Night 1: Last dose of lemborexant. Night 1 or 2: Begin trazodone 25 to 50 mg. Nights 2 through 7: Titrate trazodone by 25 mg every 3 to 5 nights to a maximum of 100 mg for sleep. Day 14: Reassess. If sleep quality is significantly worse, discuss alternative options (suvorexant, low-dose doxepin, or cognitive behavioral therapy for insomnia).

Cognitive behavioral therapy for insomnia (CBT-I) should be discussed during any medication transition. The AASM recommends CBT-I as first-line treatment for chronic insomnia in adults, and a medication switch is an ideal moment to introduce or reinforce behavioral interventions [5].